SCHEMBL4470869

SCHEMBL4470869

CCc1c(OC(C)=O)c(C)c(C)c2c1C(=O)CC1(CCC1)O2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.35
ALDH1A1 P00352 5/20 0.35
HPGD P15428 3/20 0.35
HSD17B10 Q99714 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KLK7 P49862 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
PDE4A P27815 1/20 0.34
PDE3A Q14432 1/20 0.34
TTPA P49638 3/20 0.33
ALOX5 P09917 1/20 0.33
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.32
GAA P10253 1/20 0.31
CASP1 P29466 1/20 0.31
IMPDH2 P12268 1/20 0.30
IMPDH1 P20839 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468788 0.87 KMT2A (0.38) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL4464207 0.80 PTPN1 (0.35) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL4464500 0.76 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL4468435 0.73 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL4466864 0.72 ALOX5 (0.35) KMT2AMEN1PDE4APDE3ATTPA
SCHEMBL4466861 0.72 ALOX5 (0.35) KMT2AMEN1PDE4APDE3ATTPA
SCHEMBL4466400 0.71 KDM4E (0.33) KDM4EALDH1A1HPGDHTTATM
SCHEMBL4462456 0.70 KDM4E (0.41) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL4481625 0.69 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL10974121 0.68 MEN1 (0.37) ALDH1A1KMT2AMEN1PDE4APDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 KDM4E 3310/4885ALDH1A1 169/4885HPGD 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.